Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cellink AB (publ)

Healthcare US CLLKF

1.762USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

1.981.98
LowHigh

52 Week Range

1.783.95
LowHigh

Fundamentals

  • Previous Close 1.76
  • Market Cap163.35M
  • Volume200
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-127.50000M
  • Revenue TTM1780.10M
  • Revenue Per Share TTM25.22
  • Gross Profit TTM 938.00M
  • Diluted EPS TTM-2.43

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Income before tax -1573.44305M -70.60000M -797.30000M -753.10000M -753.10000M
Minority interest 4.20M 3.60M 1.10M 2.80M 2.80M
Net income -1086.16846M -5.50000M -1172.70000M -832.90000M -832.90000M
Selling general administrative 303.50M 552.30M 986.20M 719.00M 719.00M
Selling and marketing expenses - 425.70M - - -
Gross profit 580.44M 1007.30M 993.30M 1830.60M 1830.60M
Reconciled depreciation 1271.60M 478.30M 1144.20M 940.60M 940.60M
Ebit -251.46760M -284.00000M - -618.30000M -618.30000M
Ebitda -34.81245M -111.10000M - 322.30M 322.30M
Depreciation and amortization 216.66M 172.90M - 940.60M 940.60M
Non operating income net other - - - - -
Operating income -251.46760M -289.10000M -293.30000M -996.90000M -996.90000M
Other operating expenses 1744.91M 2235.40M - 3257.30M 3257.30M
Interest expense 321.59M 97.60M 95.90M 98.20M 98.20M
Tax provision 6.40M 23.10M -8.60000M 82.60M 82.60M
Interest income 37.60M 17.90M 18.30M 6.80M 6.80M
Net interest income -284.80000M -74.00000M -84.60000M -108.10000M -108.10000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 6.38M 23.10M - 82.60M 82.60M
Total revenue 1493.44M 1946.30M 2010.40M 2239.50M 2239.50M
Total operating expenses 831.91M 1296.40M 2303.80M 2848.40M 2848.40M
Cost of revenue 913.00M 939.00M 1017.20M 408.90M 408.90M
Total other income expense net -1321.97545M 218.50M - 243.80M 243.80M
Discontinued operations - - - - -
Net income from continuing ops -1583.70000M -93.70000M -788.70000M -835.70000M -835.70000M
Net income applicable to common shares - - - -832.90000M -832.90000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Total assets 3687.33M 5483.20M 7897.80M 10196.80M 10196.80M
Intangible assets 519.50M 825.80M 1203.40M 1439.20M 1439.20M
Earning assets - - - - -
Other current assets 96.96M 1459.95M - 0.10M 0.10M
Total liab 1943.01M 2475.60M 2989.90M 3264.60M 3264.60M
Total stockholder equity 1744.21M 2985.00M 4907.90M 6905.00M 6905.00M
Deferred long term liab - - - 462.10M 462.10M
Other current liab 178.85M 397.60M 78.90M 526.80M 709.20M
Common stock 1.80M 1.80M - 1.80M 1.80M
Capital stock 1.80M 1.80M 1.80M 1.80M 1.80M
Retained earnings -5936.86974M -4861.80000M -3094.40000M -1106.60000M -1106.60000M
Other liab - - - 569.70M 569.70M
Good will 775.20M 2170.90M 3822.80M 5273.70M 5273.70M
Other assets - - - 604.00M 604.00M
Cash 1278.98M 598.00M 804.10M 925.20M 925.20M
Cash and equivalents - - - - -
Total current liabilities 1570.85M 570.80M 847.00M 939.50M 939.50M
Current deferred revenue 256.65M - - 594.80M 594.80M
Net debt 222.24M 1165.40M 618.20M 927.90M 927.90M
Short term debt 1065.92M 93.80M - 97.70M 97.70M
Short long term debt 1004.80M 6.70M 6.50M 8.00M 8.00M
Short long term debt total 1501.22M 1763.40M - 1853.10M 1853.10M
Other stockholder equity 7582.03M 7845.00M - 8009.80M 8009.80M
Property plant equipment - - - 901.60M 901.60M
Total current assets 2000.27M 1854.30M 2040.90M 2437.00M 2437.00M
Long term investments - - - - -
Net tangible assets - - - 654.20M 654.20M
Short term investments - - - - -
Net receivables 428.42M 50.18M 520.00M 1018.60M 1018.60M
Long term debt 0.20M 1337.10M 1415.80M 1384.90M 1384.90M
Inventory 195.91M 259.00M 405.20M 493.10M 493.10M
Accounts payable 69.43M 77.90M 170.20M 132.60M 132.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 97.26M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -2.60000M 42.90M -0.10000M 43.60M 43.60M
Deferred long term asset charges - - - - -
Non current assets total 1687.06M 3628.90M 5856.90M 7759.80M 7759.80M
Capital lease obligations 281.90M 419.60M 536.00M 460.20M 460.20M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2022-08-31
Investments 5.50M -4.10000M 189.70M 212.90M 212.90M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities 707.52M 128.00M - 212.90M 212.90M
Net borrowings -347.80000M -105.60000M -6.40000M -78.10000M -78.10000M
Total cash from financing activities -453.95837M -200.70000M - 455.30M 455.30M
Change to operating activities - - - 85.40M 85.40M
Net income -1575.63753M 8.10M -1983.20000M -753.10000M -753.10000M
Change in cash 493.83M 85.30M 133.60M 444.00M 444.00M
Begin period cash flow 785.15M 861.00M 378.70M 481.20M 481.20M
End period cash flow 1278.98M 946.30M 680.50M 925.20M 925.20M
Total cash from operating activities 68.23M 158.40M -72.10000M -269.40000M -269.40000M
Issuance of capital stock -0.20000M 3.60M 493.00M 540.60M 540.60M
Depreciation 216.66M 478.30M 1929.30M 940.60M 940.60M
Other cashflows from investing activities - -43.20000M - 705.20M -
Dividends paid - - - - -
Change to inventory 15.96M 92.20M -122.10000M -162.10000M -162.10000M
Change to account receivables -1.89523M 124.10M - -189.40000M -189.40000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -106.83134M 3.28M - -81.00000M -81.00000M
Change to netincome - - - 508.60M 508.60M
Capital expenditures 13.27M 44.10M 454.10M 529.60M 529.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 112.52M 48.60M -110.60000M -266.10000M -266.10000M
Stock based compensation 3.20M 2.10M -20.10000M 39.00M 39.00M
Other non cash items 1314.69M -378.70000M -113.50000M -229.80000M -229.80000M
Free cash flow 54.96M 114.30M -643.00000M -799.00000M -799.00000M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLLKF
Cellink AB (publ)		 - -% 1.76 - - 1.03 0.86 1.06 70.69
ABT
Abbott Laboratories		 0.53 0.59% 91.06 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 4.65 1.50% 314.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.31 0.38% 80.32 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.845 1.85% 44.76 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.

Cellink AB (publ)

Grafiska vägen 2B, Gothenburg, Sweden, 412 63

Key Executives

Name Title Year Born
Mr. Erik Gatenholm Co-Founder, CEO, Pres & Director 1989
Dr. Hector Martinez Exec. VP, Co-Founder & CTO 1985
Mr. Mikael Engblom Interim Chief Financial Officer 1977
Ms. Asa Hillsten Sr. VP & Head of Investor Relations 1975
Lotta Bus SVP, Gen. Counsel & Sec. 1970
Ms. Karin Danielsson Global HR Director 1982
Ms. Erica Bell Sr. VP & Chief People Officer 1973
Mr. Artur Aira Sr. VP & Bus. Area Director - Bioprinting 1967
Ms. Itedale Namro Redwan Chief Scientific Officer - Bioprinting NA
Niclas Emanuelsson Head of Global Operations 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions